Valve disease due to appetite suppressants (cont'd).
(1) The risk of cardiac valve disease linked to appetite suppressants has now been confirmed by several studies.  It seems to increase with the duration of treatment.  (2) The outcome after treatment cessation is poorly known.  (3) Patients exposed to these drugs should continue to be monitored.
D001021:Aortic Valve / Q000187:drug effects*; D001067:Appetite Depressants / Q000009:adverse effects; D002986:Clinical Trials as Topic; D020372:Dexfenfluramine / Q000009:adverse effects; D005277:Fenfluramine / Q000009:adverse effects; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D008943:Mitral Valve / Q000187:drug effects*; D010645:Phentermine / Q000009:adverse effects; D017367:Selective Serotonin Reuptake Inhibitors; D016896:Treatment Outcome
D001067:Appetite Depressants; D020372:Dexfenfluramine; D005277:Fenfluramine; D010645:Phentermine; D017367:Selective Serotonin Reuptake Inhibitors